A brief view of Yozma's enduring
capacity for successful
The select cases below demonstrate the special capacity of Yozma to identify early-stage companies with highly-differentiated technologies, to add significant value to these companies, and attract world leading strategic and financial investors.
Yozma was the sole Israeli investor in BioSense, a Medical Technology company that developed the first effective treatment in the world for cardiac rhythm disturbance called ventricular tachycardia (VT).
In October 1997, Johnson & Johnson (NYSE: JNJ) acquired BioSense for nearly a half a billion dollars, representing the single largest acquisition of an Israeli technology company up to that time.
Yozma was the founding/seed investor in Telegate, a communications company that developed infrastructure for telephony over cable TV.
Since its initial investment in Telegate in March 1994, Yozma provided the company with extensive support in developing its business direction and in attracting strategic investors such as General Instruments (NYSE: GIC) and ECI Telecom (NASDAQ: ECIL).
In December 1999, Telegate was acquired by Terayon Communications (NASDAQ: TERN).
Yozma was the founding/seed investor in E-Sim, a software company that develops Web-based products for the embedded systems market.
Yozma provided E-Sim with extensive support in positioning itself for an IPO. In July 1998, E-Sim went public in the US (NASDAQ: ESIM). In October 1999, America On Line (NYSE: AOL) made a significant strategic investment in E-SIM coupled with a strategic partnership with the company.
In July 1998, E-Sim went public in the US (NASDAQ: ESIM). In October 1999, America On Line (NYSE: AOL) made a significant strategic investment in E-SIM coupled with a strategic partnership with the company.